Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.510,61
-0,60%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NextCure Inc (NXTC) NextCure Inc (NXTC) Notizie

NextCure Inc

NXTC
1,48
-0,01 (-0,67%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:05GLOBENextCure Provides Business Update and Reports First Quarter..
24/4/202422:05GLOBENextCure to Present Phase 1b Data of NC410 in Combination..
08/4/202413:00GLOBENextCure and LCB Present Preclinical Data on B7-H4 Antibody..
04/4/202413:05GLOBENextCure Appoints Dr. Rakesh Dixit to Scientific Advisory..
02/4/202413:00GLOBENextCure to Present at 23rd Annual Needham Virtual..
21/3/202413:55GLOBENextCure Provides Business Update and Reports Full Year 2023..
05/3/202414:05GLOBENextCure Publishes Preclinical Data Demonstrating Function..
01/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:05GLOBENextCure Presents Preclinical Data on a Novel Therapeutic..
21/12/202313:05GLOBENextCure Publishes Non-Clinical Data Demonstrating..
14/12/202313:15EDGAR2Form 8-K - Current report
14/12/202312:45GLOBENextCure Provides Year-End Clinical Pipeline Updates
20/11/202313:00GLOBENextCure to Present at the 35th Annual Piper Sandler..
15/11/202322:05GLOBENextCure Publishes Non-Clinical Data Defining the Mechanism..
02/11/202321:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:10EDGAR2Form 8-K - Current report
02/11/202321:05GLOBENextCure Provides Business Update and Reports Third Quarter..
17/10/202314:05GLOBEPreclinical Data Demonstrate Anti-Siglec-15 Treatment..
26/9/202322:05GLOBENextCure Presents Preclinical Data on NC181, a Novel..
12/9/202314:05GLOBEA Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in..
07/9/202322:05GLOBENextCure and Nordic Bioscience Publish Review Article on the..
05/9/202322:05GLOBEPreclinical Data Demonstrate Potential Application of..
31/8/202313:00GLOBENextCure to Present at the H.C. Wainwright 25th Annual..
04/8/202322:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/8/202322:30EDGAR2Form S-3 - Registration statement under Securities Act of..
03/8/202322:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:16EDGAR2Form 8-K - Current report
03/8/202322:05GLOBENextCure Provides Business Update and Reports Second Quarter..
19/7/202322:05EDGAR2Form 8-K - Current report
21/6/202322:05GLOBENextCure Presents Non-Clinical Data Defining the Mechanism..
09/5/202313:00GLOBENextCure to Present at the JMP Securities Life Sciences..
Apertura: 1,60 Min: 1,49 Max: 1,60
Chiusura: 1,49

La tua Cronologia

NASDAQ
NXTC
NextCure
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network